530125 — Samrat Pharmachem Income Statement
0.000.00%
Last trade - 00:00
- IN₹1.09bn
- IN₹1.08bn
- IN₹2.82bn
- 32
- 37
- 38
- 24
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,375 | 1,790 | 2,218 | 3,106 | 2,816 |
Cost of Revenue | |||||
Gross Profit | 118 | 148 | 319 | 328 | 113 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,312 | 1,709 | 1,981 | 2,874 | 2,798 |
Operating Profit | 62 | 81.6 | 237 | 233 | 18.2 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 57.8 | 73.4 | 236 | 225 | 25.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | 42.4 | 53.3 | 172 | 166 | 21.6 |
Net Income Before Extraordinary Items | |||||
Net Income | 42.4 | 53.3 | 172 | 166 | 21.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 42.4 | 53.3 | 172 | 166 | 21.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 13.7 | 17.3 | 55.7 | 53.8 | 7 |
Dividends per Share |